Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation: A Randomized Controlled Study
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 214
- 试验地点
- 1
- 主要终点
- acute kidney injury
研究概览
简要总结
Acute kidney injury (AKI) following liver transplantation (LT) is associated with increased costs, morbidity, and mortality. Dexmedetomidine has known to have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.
详细描述
Acute kidney injury (AKI) following liver transplantation (LT) has shown a wide range of incidence between 17% and 95% and is associated with increased costs, morbidity, and mortality. The etiology of AKI after LT is multifactorial. Among these factors, renal ischemia-reperfusion injury (IRI) caused by perioperative renal hypoperfusion is considered as one of the most important independent risk factors and recent reports have indicated that IRI is associated with an inflammatory cascade. Dexmedetomidine which is a highly selective agonist of α2-adrenergic receptors has known have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 20 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •living liver transplantation recipients
排除标准
- •preoperative renal dysfunction
- •dual living donor liver transplantation
- •severe cerebral artery disease
- •severe cardio-pulmonary disease
研究组 & 干预措施
control group
The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
干预措施: Normal saline (Drug)
treatment group
The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
干预措施: Dexmedetomidine (Drug)
结局指标
主要结局
acute kidney injury
时间窗: 7 days
serum creatinine levels in postoperative 7 days
次要结局
- delirium(postoperative day 7)
- graft failure(1 year)
- lactate level(3 days)
- early allograft dysfunction(postoperative day 7)
- duration of mechanical ventilation(up to 1 year)
- hospital length of stay(up to 1 year)
- intensive care unit length of stay(up to 1 year)
研究者
Jun-Gol Song
Professor
Asan Medical Center